Why Pheon Is Keeping Mum Over Target For Novel ADC

Intense competition in ADCs means Pheon is holding back details on its technology as it heads into Phase I studies after a $120m series B fundraising.

Antibody Drug Conjugate
• Source: Shutterstock

Pheon has just raised $120m in a series B round to fund early-stage trials of its new antibody drug conjugate technology, but is keeping the novel target’s identity under wraps for now, conscious of the intense competition in the field.

The UK-headquartered firm has been around since 2015, and has been able to attract the funding now that the ADC...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip